Maíra Peres Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maíra Peres Ferreira has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Osvaldo de Freitas
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
12 shared publications - Fabiana Testa Moura de Carvalho Vicentini
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil
6 shared publications - Vinícius Pedrazzi
Department of Dental Materials and Prosthodontics, School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
6 shared publications - Renê Oliveira Do Couto
Federal University of São João Del-Rei, Brazil
5 shared publications - Natália Floriano Paiva
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
4 shared publications - Ana Paula Macedo
Department of Dental Materials and Prosthesis, School of Dentistry of Ribeirão Preto University of São Paulo Ribeirão Preto Brazil
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 62
PHOTOPROTECTIVE EFFICACY OF ROBUSTA GREEN COFFEE (Coffea canephora) EXTRACT AND LINSEED (Linum usitatissimum) OIL-BASED NANOEMULSIONS AGAINST UVB-INDUCED DAMAGE TO THE SKIN
This study adopted a preclinical model to develop and evaluate the photoprotective efficacy of nanoemulsions (NEs) containing Robusta green coffee extract (GCE) and linseed oil (LO) against UVB-induced skin damage. The GCE, rich in polyphenols and caffeine, demonstrated antioxidant activity in vitro. The LO met quality standards based on physicochemical analyses (peroxide, acid, and saponification values), confirming its suitability for formulation. Using Chremophor® RH 40 and Span® 80 as surfactants yielded stable and nanometric NEs, since both the control with only LO (NE-C) and the NEs loaded with GCE at concentrations of 0.25% (NE-0.25), 0.5% (NE-0.5), and 1.0% (NE-1.0) showed D50 < 90 nm, PDI ≤ 0.2, and ZP < -26.0 mV. Morphological studies confirmed a spherical shape and uniform droplet distribution, with no aggregation. Moreover, all NEs presented a pH of around 5, compatible with human skin. The NEs were topically applied to the dorsal skin of hairless mice before and after UVB exposure. Besides being well tolerated following an acute irritation test, NE-0.25 markedly reduced neutrophil migration (49%) while recovering the skin antioxidant capacity (catalase activity and reduced glutathione levels) to near-baseline values within 12 h of UVB exposure, thus highlighting its potential as a skin anti-aging strategy.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 62
Open AccessPHOTOPROTECTIVE EFFICACY OF ROBUSTA GREEN COFFEE (Coffea canephora) EXTRACT AND LINSEED (Linum usitatissimum) OIL-BASED NANOEMULSIONS AGAINST UVB-INDUCED DAMAGE TO THE SKIN
This study adopted a preclinical model to develop and evaluate the photoprotective efficacy of nanoemulsions (NEs) containing Robusta green coffee extract (GCE) and linseed oil (LO) against UVB-induced skin damage. The GCE, rich in polyphenols and caffeine, demonstrated antioxidant activity in vitro. The LO met quality standards based on physicochemical analyses (peroxide, acid, and saponification values), confirming its suitability for formulation. Using Chremophor® RH 40 and Span® 80 as surfactants yielded stable and nanometric NEs, since both the control with only LO (NE-C) and the NEs loaded with GCE at concentrations of 0.25% (NE-0.25), 0.5% (NE-0.5), and 1.0% (NE-1.0) showed D50 < 90 nm, PDI ≤ 0.2, and ZP < -26.0 mV. Morphological studies confirmed a spherical shape and uniform droplet distribution, with no aggregation. Moreover, all NEs presented a pH of around 5, compatible with human skin. The NEs were topically applied to the dorsal skin of hairless mice before and after UVB exposure. Besides being well tolerated following an acute irritation test, NE-0.25 markedly reduced neutrophil migration (49%) while recovering the skin antioxidant capacity (catalase activity and reduced glutathione levels) to near-baseline values within 12 h of UVB exposure, thus highlighting its potential as a skin anti-aging strategy.
- 6 September 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (11) , 103985
Production of apoferritin/chitosan complex by Maillard reaction as a promising platform to enhance pDNA delivery
- 6 September 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (11) , 103985
Production of apoferritin/chitosan complex by Maillard reaction as a promising platform to enhance pDNA delivery
- 18 December 2024
- Published by Springer Nature in BioNanoScience
- Vol. 15 (1) , 1-18
Ferritin-Based Systems as a Platform for DNA Construct Delivery: Preparation, Characterization, and In Vitro Evaluation
- 18 December 2024
- Published by Springer Nature in BioNanoScience
- Vol. 15 (1) , 1-18
Ferritin-Based Systems as a Platform for DNA Construct Delivery: Preparation, Characterization, and In Vitro Evaluation
- 28 November 2024
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 206, 114589
Self-assembled nanovaccine based on apoferritin: Development and vaccine regimen evaluation
- 28 November 2024
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 206, 114589
Self-assembled nanovaccine based on apoferritin: Development and vaccine regimen evaluation
- Open Access
- 12 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1198
Assessing α-Bisabolol as a Transmucosal Permeation Enhancer of Buccal Local Anesthetics
Needle-free buccal anesthesia improves dental treatment outcomes for both patients and dentists. In this study, we report on an assessment of the enhancement effects of α-bisabolol on the in vitro transmucosal permeation of prilocaine hydrochloride (PCl) and lidocaine hydrochloride (LCl) from needleless buccal films. We also evaluated the mechanical properties of the film, which consisted of Methocel™ K100 LV as the film-forming polymer (3% m·m−1), PEG 400 as a cosolvent (15% m·m−1 based on drug loading), α-bisabolol (15 and 30% m·m−1 based on drug loading), and the drugs combined at a 1:1 ratio (15 mg·unit−1). The porcine esophageal epithelium was used as a membrane barrier, and artificial saliva was the release medium. After a 1 h experiment at 25 ± 2 °C, α-bisabolol significantly decreased, rather than enhanced, the permeation fluxes (five-fold), permeability coefficients (seven-fold), and retentions (two-fold) of both PCl and LCl through the epithelium, regardless of the concentration. Moreover, the resistance and flexibility of the films markedly decreased compared to those without α-bisabolol. Therefore, under the experimental conditions, using α-bisabolol as a buccal permeation enhancer for the hydrophilic local anesthetics PCl and LCl from buccal films is not feasible.
- 12 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1198
Open AccessAssessing α-Bisabolol as a Transmucosal Permeation Enhancer of Buccal Local Anesthetics
Needle-free buccal anesthesia improves dental treatment outcomes for both patients and dentists. In this study, we report on an assessment of the enhancement effects of α-bisabolol on the in vitro transmucosal permeation of prilocaine hydrochloride (PCl) and lidocaine hydrochloride (LCl) from needleless buccal films. We also evaluated the mechanical properties of the film, which consisted of Methocel™ K100 LV as the film-forming polymer (3% m·m−1), PEG 400 as a cosolvent (15% m·m−1 based on drug loading), α-bisabolol (15 and 30% m·m−1 based on drug loading), and the drugs combined at a 1:1 ratio (15 mg·unit−1). The porcine esophageal epithelium was used as a membrane barrier, and artificial saliva was the release medium. After a 1 h experiment at 25 ± 2 °C, α-bisabolol significantly decreased, rather than enhanced, the permeation fluxes (five-fold), permeability coefficients (seven-fold), and retentions (two-fold) of both PCl and LCl through the epithelium, regardless of the concentration. Moreover, the resistance and flexibility of the films markedly decreased compared to those without α-bisabolol. Therefore, under the experimental conditions, using α-bisabolol as a buccal permeation enhancer for the hydrophilic local anesthetics PCl and LCl from buccal films is not feasible.
- Open Access
- 23 August 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1108
Metronidazole Modified-Release Therapy Using Two Different Polymeric Systems Gels or Films: Clinical Study for the Treatment of Periodontitis
This study evaluated the efficacy of semisolid systems (gels) and films containing a combination of metronidazole (MTZ) and metronidazole benzoate after scaling and root-planing (SRP) for periodontitis. In total, 45 patients with stage I or II periodontitis were enrolled and divided into 3 groups: 1—SRP—control; 2—SRP + Film with MTZ; 3—SRP + Gel with MTZ. The pH of gingival crevicular fluid (GCF) before/after treatments, MTZ concentrations, and drug release using high-performance liquid chromatography were investigated. The effects were evaluated by longitudinal monitoring of clinical parameters (probing depth—PD, clinical attachment level—CAL, and bleeding on probing—BP). MTZ and MTZ-benzoate concentrations in the periodontal pocket and pH showed no statistical difference after application. SRP + Gel presented the lowest CAL values. For SRP + Film and SRP + Gel, higher PD values were observed at T0 compared to all groups. A relevant reduction in BP was observed in SRP + Film and SRP + Gel groups at all times compared to T0. Both therapies improved periodontal health compared to SRP alone, reducing PD and BP, and increasing CAL for the gel group, suggesting they are promising for periodontal disease treatment.
- 23 August 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1108
Open AccessMetronidazole Modified-Release Therapy Using Two Different Polymeric Systems Gels or Films: Clinical Study for the Treatment of Periodontitis
This study evaluated the efficacy of semisolid systems (gels) and films containing a combination of metronidazole (MTZ) and metronidazole benzoate after scaling and root-planing (SRP) for periodontitis. In total, 45 patients with stage I or II periodontitis were enrolled and divided into 3 groups: 1—SRP—control; 2—SRP + Film with MTZ; 3—SRP + Gel with MTZ. The pH of gingival crevicular fluid (GCF) before/after treatments, MTZ concentrations, and drug release using high-performance liquid chromatography were investigated. The effects were evaluated by longitudinal monitoring of clinical parameters (probing depth—PD, clinical attachment level—CAL, and bleeding on probing—BP). MTZ and MTZ-benzoate concentrations in the periodontal pocket and pH showed no statistical difference after application. SRP + Gel presented the lowest CAL values. For SRP + Film and SRP + Gel, higher PD values were observed at T0 compared to all groups. A relevant reduction in BP was observed in SRP + Film and SRP + Gel groups at all times compared to T0. Both therapies improved periodontal health compared to SRP alone, reducing PD and BP, and increasing CAL for the gel group, suggesting they are promising for periodontal disease treatment.
- Open Access
- 4 November 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (11) , 2583
The Potential of Films as Transmucosal Drug Delivery Systems
Pharmaceutical films are polymeric formulations used as a delivery platform for administration of small and macromolecular drugs for local or systemic action. They can be produced by using synthetic, semi-synthetic, or natural polymers through solvent casting, electrospinning, hot-melt extrusion, and 3D printing methods, and depending on the components and the manufacturing methods used, the films allow the modulation of drug release. Moreover, they have advantages that have drawn interest in the development and evaluation of film application on the buccal, nasal, vaginal, and ocular mucosa. This review aims to provide an overview of and critically discuss the use of films as transmucosal drug delivery systems. For this, aspects such as the composition of these formulations, the theories of mucoadhesion, and the methods of production were deeply considered, and an analysis of the main transmucosal pathways for which there are examples of developed films was conducted. All of this allowed us to point out the most relevant characteristics and opportunities that deserve to be taken into account in the use of films as transmucosal drug delivery systems.
- 4 November 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (11) , 2583
Open AccessThe Potential of Films as Transmucosal Drug Delivery Systems
Pharmaceutical films are polymeric formulations used as a delivery platform for administration of small and macromolecular drugs for local or systemic action. They can be produced by using synthetic, semi-synthetic, or natural polymers through solvent casting, electrospinning, hot-melt extrusion, and 3D printing methods, and depending on the components and the manufacturing methods used, the films allow the modulation of drug release. Moreover, they have advantages that have drawn interest in the development and evaluation of film application on the buccal, nasal, vaginal, and ocular mucosa. This review aims to provide an overview of and critically discuss the use of films as transmucosal drug delivery systems. For this, aspects such as the composition of these formulations, the theories of mucoadhesion, and the methods of production were deeply considered, and an analysis of the main transmucosal pathways for which there are examples of developed films was conducted. All of this allowed us to point out the most relevant characteristics and opportunities that deserve to be taken into account in the use of films as transmucosal drug delivery systems.
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 30, e20210538
Preemptive analgesia with ibuprofen increases anesthetic efficacy in children with severe molar: a triple-blind randomized clinical trial
This study evaluated the effectiveness of preemptive analgesia in children with severe MIH, post-eruptive enamel breakdown, and hypersensitivity. Ibuprofen (10 mg/kg child weight) or placebo was administered, followed by infiltrative anesthesia and restoration with resin composite. Hypersensitivity was evaluated in five moments. The data were analyzed using the chi-square test, Fisher’s exact test, and t-test. Preemptive analgesia provided benefits for the treatment of severe cases of MIH, with an increase in the effectiveness of infiltrative anesthesia and improved patient comfort during the restorative procedure. Preemptive analgesia has shown efficacy in reducing hypersensitivity during restorative dental procedures, evidencing the significance of this study for patients with MIH and hypersensitivity.
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 30, e20210538
Open AccessPreemptive analgesia with ibuprofen increases anesthetic efficacy in children with severe molar: a triple-blind randomized clinical trial
This study evaluated the effectiveness of preemptive analgesia in children with severe MIH, post-eruptive enamel breakdown, and hypersensitivity. Ibuprofen (10 mg/kg child weight) or placebo was administered, followed by infiltrative anesthesia and restoration with resin composite. Hypersensitivity was evaluated in five moments. The data were analyzed using the chi-square test, Fisher’s exact test, and t-test. Preemptive analgesia provided benefits for the treatment of severe cases of MIH, with an increase in the effectiveness of infiltrative anesthesia and improved patient comfort during the restorative procedure. Preemptive analgesia has shown efficacy in reducing hypersensitivity during restorative dental procedures, evidencing the significance of this study for patients with MIH and hypersensitivity.
- 1 October 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (10) , 3450-3456
Herpes Labialis: A New Possibility for Topical Treatment with Well-Elucidated Drugs
- 1 October 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (10) , 3450-3456
Herpes Labialis: A New Possibility for Topical Treatment with Well-Elucidated Drugs
- Open Access
- 21 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (11)
O efeito da divisão na qualidade e na liberação in vitro de cloridrato de metformina de comprimidos de liberação prolongada (XR)
O cloridrato de metformina (MetCl) é usado mundialmente no tratamento do diabetes mellitus tipo 2. Embora os comprimidos de liberação prolongada (XR) contendo 500 mg, 850 mg e 1000 mg de MetCl sejam comercializados, não é incomum dividir o comprimido quando a dosagem necessária não está disponível comercialmente. O objetivo do trabalho foi avaliar os efeitos da divisão no desempenho in vitro de comprimidos XR contendo MetCl. Realizamos ensaios de controle de qualidade e estudos de perfil de dissolução comparativos entre diversos medicamentos contendo 500 mg e 1000 mg de MetCl, comercializados no Brasil e na Argentina. Comprimidos contendo 1000 mg de MetCl foram divididos pela metade (amostras de teste) e comparados com comprimidos inteiros de produtos contendo 500 mg de MetCl (amostras de referência). Os comprimidos reduzidos ao meio são mais frágeis e apresentam menor uniformidade de massa e unidade de dosagem em relação aos inteiros. No entanto, foi evidenciado pelo parâmetro de F2 bootstrapping que a divisão dos comprimidos de MetCl XR não afetou significativamente os perfis de liberação do fármaco in vitro em comparação com os comprimidos inteiros. Além disso, nem o mecanismo de liberação do fármaco nem a cinética de liberação foram significativamente afetados. Os comprimidos XR contendo 1000 mg de cloridrato de metformina podem ser elegíveis para divisão, no entanto, os fabricantes devem fornecer sulcos adequadas nas superfícies dos comprimidos para tornar a divisão adequada e mais segura para os pacientes.
- 21 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (11)
Open AccessO efeito da divisão na qualidade e na liberação in vitro de cloridrato de metformina de comprimidos de liberação prolongada (XR)
O cloridrato de metformina (MetCl) é usado mundialmente no tratamento do diabetes mellitus tipo 2. Embora os comprimidos de liberação prolongada (XR) contendo 500 mg, 850 mg e 1000 mg de MetCl sejam comercializados, não é incomum dividir o comprimido quando a dosagem necessária não está disponível comercialmente. O objetivo do trabalho foi avaliar os efeitos da divisão no desempenho in vitro de comprimidos XR contendo MetCl. Realizamos ensaios de controle de qualidade e estudos de perfil de dissolução comparativos entre diversos medicamentos contendo 500 mg e 1000 mg de MetCl, comercializados no Brasil e na Argentina. Comprimidos contendo 1000 mg de MetCl foram divididos pela metade (amostras de teste) e comparados com comprimidos inteiros de produtos contendo 500 mg de MetCl (amostras de referência). Os comprimidos reduzidos ao meio são mais frágeis e apresentam menor uniformidade de massa e unidade de dosagem em relação aos inteiros. No entanto, foi evidenciado pelo parâmetro de F2 bootstrapping que a divisão dos comprimidos de MetCl XR não afetou significativamente os perfis de liberação do fármaco in vitro em comparação com os comprimidos inteiros. Além disso, nem o mecanismo de liberação do fármaco nem a cinética de liberação foram significativamente afetados. Os comprimidos XR contendo 1000 mg de cloridrato de metformina podem ser elegíveis para divisão, no entanto, os fabricantes devem fornecer sulcos adequadas nas superfícies dos comprimidos para tornar a divisão adequada e mais segura para os pacientes.